Skip to main content
SpringerLink
Log in

Sorafenib + best supportive care (BSC) is more cost effective than BSC alone

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Tatar M, Akbulut H.Cost-effectiveness of Sorafenib in Unresectable And/or Metastatic Renal Cell Carcinoma in Turkey. 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research: (plus oral presentation) abstr. CN3, 24 Oct 2009. Available from: URL: http://www.ispor.org/Events/Index.aspx?eventId=30

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sorafenib + best supportive care (BSC) is more cost effective than BSC alone. Pharmacoecon. Outcomes News 591, 7 (2009). https://doi.org/10.2165/00151234-200905910-00012

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905910-00012

Keywords

Search

Navigation